Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...

In late 2022, the results of a groundbreaking stage-three trial for a ‘miracle’ new Alzheimer’s drug, lecanemab, were hailed ...

HealthDay News — Annual wasteful spending on discarded lecanemab is anticipated to range between $133 and $336 million, given current vial sizes, according to a research letter published online ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...

Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...

An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

STOCKHOLM, Oct. 16, 2024 /PRNewswire/ --BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public ...

Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new vial size that would reduce the amount of unused medication that is thrown ...

Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...

Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...